BRAF and MEK combos for melanoma

Update October 1, 2015- The FDA approved the use of two drugs, Opdivo and Yervoy, to treat metastatic melanoma, as we first discussed with Dr. Ribas last year. 

November 30, 2014- Interviewed by Steven E. Greer, MD

We have previously reported on Phase 2 data indicating that the combination of a BRAF and MEK inhibitor drug is more effective than BRAF-alone at treating advanced melanoma with BRAF mutations. Phase 3 data are now published, and Dr. Antoni Ribas of UCLA updates us.

This entry was posted in - Biotech, - Pharma, Oncology, UCLA. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *